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Analysis of recently available microarray expression data sets obtained from immortalized cell lines of the
individuals represented in the HapMap project have led to inconclusive comparisons across cohorts with
different ancestral continent of origin (ACOO). To address this apparent inconsistency, we applied a novel
approach to accentuate population-speciﬁc gene expression signatures for the CEU [homogeneous US resi-
dents with northern and western European ancestry (HapMap samples)] and YRI [homogenous Yoruba
people of Ibadan, Nigeria (HapMap samples)] trios. In this report, we describe how four independent data
sets point to the differential expression across ACOOo fg e n en e t w o r k si m p l i c a t e di nt r a n s f o r m i n gt h e
normal lymphoblast into immortalized lymphoblastoid cells. In particular, Werner syndrome helicase and
related genes are differentially expressed between the YRI and CEU cohorts. We further demonstrate that
these differences correlate with viral titer and that both the titer and expression differences are associated
with ACOO. We use the 14 genes most differentially expressed to construct an ACOO-speciﬁc ‘immortaliza-
tion network’ comprised of 40 genes, one of which show signiﬁcant correlation with genomic variation
(eQTL). The extent to which these measured group differences are due to differences in the immortalization
procedures used for each group or reﬂect ACOO-speciﬁc biological differences remains to be determined.
That the ACOO group differences in gene expression patterns may depend strongly on the process of trans-
forming cells to establish immortalized lines should be considered in such comparisons.
INTRODUCTION
Several recent studies of populations of different ancestral
continent of origin (ACOO) have identiﬁed ACOO-speciﬁc
gene expression differences. Because the sets of genes ident-
iﬁed in these studies are largely non-overlapping, the biologi-
cal interpretation of these results is challenging (1–6). Given
the importance to health disparities of such studies, we have
undertaken an integrative approach to determine whether
indeed there is a consistent difference. We have also added
a new study sample to further validate our ﬁndings. Cross-
population expression studies are fraught with the well-known
variability in the biology as well as the difﬁculties in compar-
ing transcriptome-wide measures from different platforms
(7,8) and the increasingly documented intrinsic biases of
expression patterns of immortalized cell lines (6). Technical
bias may affect many genes in concert, thus causing spurious
correlations in clinical data sets and false associations between
genes and clinical variables (9). The study of the transcriptome
in groups with different ACOO is particularly problematic in
that most of these studies are performed on Epstein–Barr
virus (EBV) immortalized cell lines. Speciﬁcally, the Inter-
national HapMap Project harvested peripheral blood lympho-
blasts from the homogenous Yoruba tribe from Ibadan
Nigeria (YRI) and then transformed them into immortalized
cells in vitro using the EBV. This is of potential additional rel-
evance, as the YRI population is one of the sub-Saharan popu-
lations known to suffer from an endemic childhood cancer
Burkitt lymphoma (BL), caused by the EBV that environmen-
tally saturates sub-Saharan Africa (10–13). In contrast, the
CEU [homogeneous US residents with northern and western
European ancestry (HapMap samples)] population as well as
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reported predisposition or population-speciﬁc susceptibility
to EBV infection. This raises the question of the degree to
which the reported expression differences are due to labora-
tory technique, measurement platform difference, laboratory-
speciﬁc variation in EBV-driven cell immortalization, or
COO-speciﬁc responses to EBV infection and immortaliza-
tion. To explore this question, we ﬁltered samples and genes
to accentuate population stratiﬁcation between CEU and
YRI trios. Our guiding principle was to select for samples
and genes with the highest consistency within ACOO and
the least overlap across ACOO. Our approach is outlined in
Figure 1. We analyzed four independent recent studies, three
of which were conducted on immortalized cell lines previously
published (5,14,15), to ﬁnd the reproducible differences by
ACOO across two expression array platforms (Affymetrix
and Illumina), and a fourth analysis was performed on an
expression experiment of primary lymphoid cells from
African Americans (AAs) and Caucasians (CAs) (16).
Further description of the experiments, type of array platforms
and genes analyzed are listed in Supplementary Material,
Table S1. To reduce noise from the varied measurement plat-
forms and laboratory-speciﬁc technique, this analysis was
intentionally driven to high speciﬁcity at the cost of sensitivity
(9) by the ﬁltering process, as described. Our analysis ident-
iﬁed an ‘immortalization network’ consisting of 40 genes, of
which 24 genes are differentially expressed between the
CEU and YRI populations. Furthermore, one of these genes,
Werner syndrome helicase (WRN), is signiﬁcantly correlated
with EBV titer. Subsequently, we relaxed the original aggres-
sive ﬁltering of the data and found the large majority of the
immortalization network’s genes were differentially expressed
across ACOO. Moreover, we identiﬁed a cis eQTL in gene
POLR1A in the network with respect to ACOO.
RESULTS
Identiﬁcation of initial COO differential expression
We started the analysis with the reproducibility of the
COO-speciﬁc differences in the ﬁrst study (4), across two trios
(CEU and YRI) divided into four populations: HapMap
parents (YRIp and CEUp) and separately HapMap children
(YRIc and CEUc). We selected those genes that were expressed
most consistently within the YRI and separately CEU popu-
lations,respectively,andthenidentiﬁedthoseoftheintersecting
setthatweresigniﬁcantlydifferentiallyexpressed.Theintersec-
tion of the number of consistently expressed genes within COO
across both populations differed for the parents (n ¼ 1043)
when compared with their children (n ¼ 568). The shared
set of genes that were highly consistently expressed in both
parental and child populations and that also were signiﬁcantly
Figure 1. Analytic ﬂow of the expression analysis of ACOO. Shaded boxes at the top represent independent data sets of gene expression proﬁling. The topmost
three boxes are three experiments by different investigators on two expression proﬁling platforms measuring expression in the immortalized lymphoblasts of the
YRI and CEU HapMap individuals. The fourth data set is measured on a group of children (CA and AA) who served as controls in an unrelated (autism) study.
These cells in this population were not immortalized prior to measurement. Eighty probe sets were measured as signiﬁcantly differentially expressed across the
three immortalized cell data sets. Of those, 66 were also differentially expressed in non-immortalized data set and the subsequent analysis focused on those 14
probe sets that were only differentially expressed in the immortalized cells. Twelve of those 14 probe sets were mapped to genes in IPA, and a network (dubbed
the COO Immortalization Network) of 40 genes was automatically constructed. This network was then assessed against the three original expression data sets in
two ways. First, one gene was identiﬁed as having a signiﬁcant eQTL based on the associated HapMap SNP data. Second, additional 11 genes from the immor-
talization network were differentially expressed across all three data sets in addition to the original 12 found (through a much more stringent ﬁlter).
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228 (Supplementary Material, Table S2). The biological func-
tions program signiﬁcantly enriched [as per the Ingenuity IPA
program (17)] in the differentially expressed genes included
processing and splicing of mRNA, immortalization of cells,
transcriptionandexpressionofDNA,synthesisandmetabolism
of proteins, processing and modiﬁcation of rRNA, receptor-
mediated endocytosis, transport and catabolism of proteins,
colony formation, activation of HIV type 1, ubiquitination
and cholangiocarcinoma (data not shown). Of the 228 genes
differentially expressed across ACOO, the top 20 genes most
correlatedwithWRN,usingPearsoncorrelation,wereidentiﬁed
and highlighted with an ‘ ’ in Supplementary Material,
Table S2. Of note, the viral titer (courtesy David Altshuler,
see Materials and Methods) correlated signiﬁcantly with
WRN gene expression across the ﬁltered CEU and YRI
samples from Stranger et al. (5) with an R
2 ¼ 0.69 and
regression-signiﬁcant P ¼ ,2.2   10
216 (Fig. 2A). Separ-
ately, the children’s EBV titer correlated with WRN expression
withan R
2of 0.86 andP-value of 2.89   10
213,and the parents
EBV titer correlated with WRN expression with an R
2 of 0.70
and P-value of 1.18   10
213 (data not shown). The distribution
of WRN values is much higher than the average expression of
genes in the genome across all samples, which is consistent
with previous reports of WRN having high levels of expression
in immortalized cells. The 20 genes closely correlated with
WRN also have higher mean expression across the CEU
andYRIpopulationswhencomparedwithWRNandallthetran-
scripts measured on the arrays (Fig. 2B).
Cross platform validation of differentially expressed genes
We conducted further analyses on an additional independent
CEU and YRI population’s transcriptome study. This study
Figure 2. (A) Correlation of WRN to relative EBV titer across the ﬁltered CEU and YRI samples and (B) the distribution of non-normalized WRN values and the
mean values of the 20 genes across the CEU and YRI populations and for all the transcripts measured on the arrays.
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U133 Array Set HG-U133A (15). Of the 228 genes signiﬁ-
cantly different on the Illumina platform between CEU and
YRI, there were 99 probe sets corresponding to the same
genes signiﬁcantly different on the Affymetrix platform. Of
these 99 probe sets, 21 were removed because the differential
expression was discordant (down for the YRI population on
the Illumina platform but up regulated compared to the CEU
on the Affymetrix platform) leaving 78 probe sets for further
analyses (Table 1). WRN was also among the genes that
were signiﬁcantly different on the Affymetrix HG-U133A
platform. In a third, but much smaller, data set, we applied
the aforementioned ﬁltering process on only eight CEU and
eight YRI founder males from the Affymetrix Human Focus
Array and only one gene, WRN, was found to be signiﬁcantly
different between CEU and YRI samples. That is, WRN is sig-
niﬁcantly differentially expressed in three independent studies
(4,14,15). The top disease and disorders (as per the Ingenuity
IPA program) enriched were viral function, connective tissue
disorders (immortalization), cancer, cardiovascular disease
and endocrine system disorders. WRN is among the genes in
each of the top three enriched categories. The biological func-
tions signiﬁcantly enriched in the differentially expressed
genes included processing and splicing of mRNA, cross-link
repair of DNA, viral transactivation, immortalization of
cells, transcription and expression of DNA, cell division,
colony formation, contact growth inhibition, apoptosis, cell
death, synthesis of proteins, gastric carcinoma (Table 2).
Additionally, we performed linear regression analyses to
determine the squared Pearson correlation coefﬁcients (R
2)
and p-values of the 20 genes most correlated with WRN
(dependent variable) mRNA expression in a pairwise manner
out of the 78 probe sets cross-platform validated for ACOO
differential expression. We used an R
2 cutoff of 0.7. Conse-
quently, the top 20 correlated probe sets have an R
2 between
0.69 and 0.84, and P-values ,2.2   10
216 as described in
Table 3. Sixteen (80%) of the 20 top correlated genes
grouped with WRN into one biological functions network
associated with gene expression, infection mechanism and
cancer with an enrichment P-value of 1.0   10
247. Seven of
the top 20 genes are members of the ﬁnal 12 gene set that com-
prised the immortalization network. We created an annotated
network of these 20 genes entitled the ‘Viral infection
network’, with the transcription factors MYC and P53
serving as the central hubs of this network (Fig. 3).
Identiﬁcation of ACOO immortalization sensitive genes
To further explore which subset of the COO differentially
expressed genes is speciﬁc to ACOO but not immortalization
and speciﬁc to differences in the immortalization process with
respect to ACOO, the results above were contrasted to an
expression study of non-immortalized lymphoid cells har-
vested from the peripheral blood from AA and CA children.
Figure 4 depicts a Venn diagram of the 78 signiﬁcantly differ-
entially expressed probe sets across platforms (Illumina and
Affymetrix) between the immortalized CEU/YRI cells. Of
those, 64 probe sets (82%) were conﬁrmed to be signiﬁcantly
different between the AA and CA children populations. This
left 14 probe sets (including WRN) that were differentially
expressed across the CEU and YRI in the immortalized cell
experiments.
An EBV immortalization gene network
The 14 probe sets that are signiﬁcantly different between CEU
and YRI immortalized cells that were not identiﬁed in non-
immortalized lymphoblast cells (LCs) were mapped into Inge-
nuity’s (IPA) package (Ingenuity
w Systems, www.ingenuity
.com) to determine which networks were enriched with these
genes. Twelve of the 14 probe sets were mapped into IPA
identifying 12 genes (two were unmapped ESTs) ARCN1,
ATP5B, JMJD1B, NOL7, NUP54, PFN1, POLR2B, PRCC,
PUM1, PWP1, WRN, ZNF410. The genes clustered into
three signiﬁcantly overrepresented/enriched networks with
10 genes mapped into the top-scoring network of DNA repli-
cation, recombination and repair with a P-value of 10
27.
JMJD18 and PUM1 mapped separately to Networks 2 and 3
. The 10 genes from Network 1 were exported into Ingenuity’s
Pathway editor to build a combined ‘Immortalization
Network’ that includes JMJD18 and PUM1 (colored red in
Fig. 4). There were several genes enriched in the ‘Immortali-
zation Network’ that were not part of the original 14 gene list.
Subsequent to ﬁnding the marked network enrichment score,
we relaxed the cutoffs in three ways, intra-population consist-
ency criterion, P-value cutoff and multiple test correction (see
Materials and Methods for more detail) in determining the
statistical inference of the additional genes in the Immortaliza-
tion Network, for the Illumina Platform only. By relaxing the
aggressive ﬁltering (of samples and genes) originally per-
formed to increase speciﬁcity across the noisy and different
expression platforms, an additional 11 genes (NUP62, BAT1,
PSME3, SFRS2, PLRG1, CDC5L, EXO1, FEN1, DNAJA1,
VCP and ZNF512B) were identiﬁed that have an ACOO-
signiﬁcant expression difference (Table 4) in the Immortaliza-
tion Network (colored yellow in Fig. 4).
Continent of origin (COO) eQTLs within the associated
immortalization pathway
We determined whether any of the genes in the ‘Immortaliza-
tion Network’ which had ACOO signiﬁcant expression
difference across the two immortalized and control data sets
manifested heritable eQTL differences between CEU and
YRI by using the public SNP data from NCBI build 36
(dbSNP b126) (http://ftp.hapmap.org/genotypes/2008-
10_phaseII/). There was one gene, POLR1A (colored green
in Fig. 4), with expression in the YRI cohort founders (60
samples) that associated with SNP rs12124 in a cis eQTL
(–log10 P-value ¼ 5.77   10
29). POLR1A also has ACOO
discordant expression across all three data sets. This eQTL
ﬁnding is consistent with a previous report by Stranger et al.
(data not shown).
DISCUSSION
The YRI is one of the native sub-Saharan populations suffering
from the childhood cancer pandemic BL caused by the EBV.
The International HapMap Project harvested peripheral blood
Human Molecular Genetics, 2009, Vol. 18, No. 20 3867Table 1. The 78 probe sets corresponding to 53 genes drawn from the 99 probe sets list generated from the intersection between the Illumina and Affymetrix
platforms of those genes that were the most consistently expressed within the YRI population and the CEU population, respectively, in both parents and in children
RefSeq Common Illumina Human V6 arrays Affymetrix U133A array
Illumina probe
set ID
CEUp versus YRIp (MTC:
Bonferroni)
CEUc versus YRIc (MTC:
Bonferroni)
CEU versus YRI (MTC: Benjamini–
Hochberg)
Fold difference
(log2)
P , 0.01 Fold difference
(log2)
P , 0.01 Affymetrix
probe set ID
Fold difference
(log2)
P , 0.05
1 NM_000462 UBE3A GI_19718761-A 1.811 2.87E246 1.399 7.06E223 211575_s_at 1.0903921 2.75E202
2 NM_000516 GNAS GI_18426899-A 1.215 2.05E213 1.174 2.87E205 217673_x_at 1.0949674 6.97E203
3 NM_000553 WRN GI_19924171-S 1.94 1.18E250 1.54 5.25E228 205667_at 1.1819617 6.51E203
4 NM_000938 POLR2B GI_4505940-S 1.621 1.10E238 1.431 3.83E219 201803_at 1.0732888 3.46E202
5 NM_000970 RPL6 GI_16753226-S 1.275 2.41E219 1.255 1.20E214 200034_s_at 1.1285841 1.90E204
6 NM_001001973 ATP5C1 GI_4885078-S 1.369 5.61E227 1.322 3.86E217 214132_at 1.136883 3.77E202
7 NM_001020658 PUM1 GI_13491165-S 1.425 5.04E232 1.157 1.07E206 201164_s_at 1.132332 6.73E204
8 NM_001025105 CSNK1A1 GI_34147516-S 1.759 3.37E253 1.41 4.87E220 206562_s_at 1.2095745 1.88E206
9 NM_001037637 BTF3 GI_29126237-S 1.319 1.10E227 1.343 9.34E218 208517_x_at 1.1164298 9.27E204
10 NM_001037637 BTF3 211939_x_at 1.0701255 4.22E202
11 NM_001037637 BTF3 214800_x_at 1.1117729 4.48E202
12 NM_001253 CDC5L GI_16357499-S 1.615 4.73E241 1.401 1.71E221 209055_s_at 1.2033471 3.16E203
13 NM_001253 CDC5L 209056_s_at 1.1000586 3.90E202
14 NM_001402 EEF1A1 GI_25453469-S 1.185 1.28E217 1.129 1.14E206 204892_x_at 1.0640733 4.48E202
15 NM_001402 EEF1A1 206559_x_at 1.0533731 3.46E202
16 NM_001402 EEF1A1 213477_x_at 1.0572026 2.50E202
17 NM_001655 ARCN1 GI_21626463-S 1.579 4.07E242 1.304 4.26E214 201176_s_at 1.1239741 2.60E203
18 NM_001686 ATP5B GI_32189393-S 1.403 5.41E229 1.412 1.86E222 201322_at 1.1220461 5.21E203
19 NM_002136 HNRNPA1 GI_4504444-A 1.43 1.26E234 1.297 4.39E218 201054_at 1.1059377 1.13E203
20 NM_002136 HNRNPA1 201055_s_at 1.1102453 2.44E202
21 NM_002136 HNRNPA1 200016_x_at 1.1229433 9.27E204
22 NM_002136 HNRNPA1 214280_x_at 1.0547829 2.69E202
23 NM_002136 HNRNPA1 213356_x_at 1.1725581 5.58E203
24 NM_002568 PABPC1 GI_4505574-S 1.248 6.13E218 1.188 1.31E208 215157_x_at 1.0570977 3.90E202
25 NM_002734 PRKAR1A GI_33636720-S 1.338 2.02E226 1.174 2.32E207 200604_s_at 1.2528985 6.87E203
26 NM_002799 PSMB7 GI_23110926-S 1.252 5.01E210 1.361 9.07E213 200786_at 1.0921669 3.01E202
27 NM_003074 SMARCC1 GI_21237801-S 1.39 3.16E227 1.305 3.01E216 201072_s_at 1.2108523 6.51E203
28 NM_003074 SMARCC1 201073_s_at 1.1169357 1.44E202
29 NM_003074 SMARCC1 201074_at 1.1553272 1.68E203
30 NM_003074 SMARCC1 201075_s_at 1.3044553 7.31E204
31 NM_003079 SMARCE1 GI_21264354-S 1.514 1.96E236 1.469 1.39E222 211988_at 1.1161661 1.52E202
32 NM_003079 SMARCE1 211989_at 1.1394086 5.06E205
33 NM_003188 MAP3K7 GI_21735565-A 1.519 1.70E240 1.283 2.45E218 206854_s_at 1.1580838 6.36E203
34 NM_003188 MAP3K7 211536_x_at 1.2212324 2.60E203
35 NM_003188 MAP3K7 211537_x_at 1.2388926 1.68E203
36 NM_003292 TPR GI_4507658-S 1.163 2.08E208 1.245 7.99E212 201731_s_at 1.155994 1.33E205
37 NM_003292 TPR 215220_s_at 1.157391 9.27E204
38 NM_003463 PTP4A1 GI_17986281-S 1.772 1.61E249 1.423 2.23E219 200730_s_at 1.4767935 1.21E205
39 NM_003463 PTP4A1 200731_s_at 1.3223011 1.32E206
40 NM_003463 PTP4A1 200732_s_at 1.4044188 7.38E210
41 NM_003463 PTP4A1 200733_s_at 1.1612434 2.42E203
42 NM_003910 BUD31 GI_32171174-S 1.552 5.62E239 1.487 1.90E223 205690_s_at 1.2200912 3.01E204
43 NM_004500 HNRNPC GI_14110430-A 1.243 1.69E218 1.317 8.75E218 216559_x_at 1.4150078 3.95E204
44 NM_004500 HNRNPC 221919_at 1.3094529 1.21E205
45 NM_004500 HNRNPC 200751_s_at 1.2383838 3.26E206
46 NM_004559 YBX1 GI_34098945-S 1.372 3.29E229 1.206 1.88E210 208628_s_at 1.0818504 4.22E202
47 NM_005022 PFN1 GI_16753213-S 1.194 5.56E214 1.245 1.92E215 200634_at 1.1045147 4.77E202
48 NM_005594 NACA GI_40254826-S 1.218 2.56E217 1.117 0.000161 208635_x_at 1.0518152 2.50E202
49 NM_005778 RBM5 GI_5032030-S 1.288 1.78E219 1.209 2.07E208 209936_at 1.1065431 2.62E202
50 NM_005791 MPHOSPH10 GI_31317304-S 1.627 2.44E232 1.576 3.59E227 212885_at 1.1840862 1.29E204
51 NM_005973 PRCC GI_40807446-S 1.568 2.08E242 1.325 5.83E213 208938_at 1.1030719 1.33E202
52 NM_006627 POP4 GI_5729985-S 1.344 1.35E221 1.313 7.84E217 202868_s_at 1.0857801 4.23E202
53 NM_006628 ARPP-19 GI_19923363-S 1.568 9.80E238 1.342 3.23E217 221483_s_at 1.1252328 1.47E202
54 NM_006766 MYST3 GI_5803097-S 1.196 1.23E210 1.327 1.76E215 216361_s_at 1.0696214 2.00E202
55 NM_006805 HNRPA0 GI_14110425-S 1.293 2.06E213 1.373 1.90E214 212626_x_at 1.1094681 1.74E202
56 NM_006805 HNRPA0 214737_x_at 1.1395135 3.40E202
57 NM_006838 METAP2 GI_27597083-S 1.582 2.78E236 1.364 7.26E222 213899_at 1.1602293 2.20E203
58 NM_007062 PWP1 GI_5902033-S 1.533 2.72E236 1.411 1.30E221 201608_s_at 1.1194986 4.62E203
59 NM_007363 NONO GI_34932413-S 1.192 1.27E211 1.218 1.28E215 208698_s_at 1.2085309 4.91E203
60 NM_007363 NONO 210470_x_at 1.1560814 1.66E202
61 NM_012245 SNW1 GI_18860912-S 1.371 2.14E225 1.334 9.62E216 215424_s_at 1.168398 7.76E203
62 NM_014077 FAM32A GI_7661695-S 1.315 3.44E224 1.24 2.80E212 201863_at 1.0926882 2.40E203
Continued
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immortalized cells using EBV in vitro. This raised the question
ofthedegreetowhichthepreviouslyreportedexpressiondiffer-
ences are due to laboratory technique, measurement platform
difference, laboratory-speciﬁc variation in EBV-driven cell
immortalization or COO-speciﬁc responses to EBV infection
and immortalization. To explore this question we tailored the
approach outlined in Figure 1. This analysis led to the identiﬁ-
cation of an immortalization network characterizing the
expression differences speciﬁc to the immortalization process
of the CEU and YRI samples across three independent studies
(4,14,15) and distinct from a fourth independent study of
ACOO differences in non-immortalized cells of AA and CA
cohorts (16). Of note, one of the genes in this network, WRN,
a gene mutated in Werner Syndrome (WS), a recessive
genetic disorder associated with a complex premature ageing
phenotype, has been shown to modulate the efﬁciency of
EBV immortalization of LC lines (18,19), possibly through its
role in the stabilization of telomeres and telomerase and the
immortalized genome (20,21). Likewise, the expression of
WRN (and the other genes in the immortalization network) is
highly correlated with EBV titer (Fig. 2). Sixteen (80%) of
the top 20 genes most correlated with WRN and sixteen
(80%)of its twenty most correlated genes grouped into one bio-
logical functions network associated with gene expression,
infection mechanism and cancer here termed ‘Viral infection
network’. Seven of the top 20 genes of the viral infection
network are part of the ﬁnal 12 genes that framed the immorta-
lization network. At the center of this network are transcription
factors MYC and P53. The MYC gene recently reported by
Faumant et al. (22) was to be one of the two ‘master’ transcrip-
tional systems activated in latency III program of EBV immor-
talization of B-cells. Among their reported major players in the
EBV immortalization process are EXO1 and FEN1 which both
directly bind to WRN and are signiﬁcantly different and
enriched in our reported immortalization network. In addition,
p53 is among the genes in the viral infection network and was
reported recently by Yi et al. (23) to have its transcriptional
and apoptotic activities modulated by the EBV protein
EBNA3C latent antigen essential for in vitro B-cell immortali-
zation. This analysis does not rule out the possibility that all the
observed COOdifferences are afunction ofabatch effect ofthe
different times, techniques and laboratories involved in the
immortalization process of the different HapMap populations
even with observed differences in three sets of experiments.
However, POLR1A’s signiﬁcantly up-regulated expression
and the speciﬁc eQTL within the YRI founders may play a
role in this population’s increased sensitivity to EBV infection.
Albeit circumstantial evidence, recently published by Michiels
et al. (24) supports a possible role of POLR1A as a marker for
head-and-neck cancers. Additionally, research by Shiratori
et al. (25) reported that in WS ﬁbroblasts, the WRN gene pro-
motes rRNA transcription as a component of an RNA polymer-
ase I(RPI)-associatedcomplex,ofwhichPOLR1A isoneofthe
core subunits (26). The Shiratori et al.’s study identiﬁed
decreased levels of rRNA transcription compared with wild-
type cells as a measurable marker for characterizing the prema-
ture aging of WS. They further showed how ﬁbroblast cells in
the presence of wild-type WRN increased rRNA levels and
cellproliferation.Althoughfurtherstudiesarerequiredtoeluci-
date POLR1A’s role in EBV-transformed B-cell, our ﬁndings
shed light on POLR1A as a component of the EBV in vitro
cell immortalization process with a possible ACOO hereditary
signature. The ﬁndings presented here are consistent with the
yet unproven hypothesis that these in vitro results echo popu-
lation health; that is, lymphoblastoid cell lines sensitivity to
EBV immortalization may mirror the EBV infection pandemic
in Central Africa. The aforementioned data are presented as
initial evidence of a set of genes that differ in expression by
ACOOandamongthemasubsetofgenesthatisenvironmentally
Table 1. Continued
RefSeq Common Illumina Human V6 arrays Affymetrix U133A array
Illumina probe
set ID
CEUp versus YRIp (MTC:
Bonferroni)
CEUc versus YRIc (MTC:
Bonferroni)
CEU versus YRI (MTC: Benjamini–
Hochberg)
Fold difference
(log2)
P , 0.01 Fold difference
(log2)
P , 0.01 Affymetrix
probe set ID
Fold difference
(log2)
P , 0.05
63 NM_014607 UBXD2 GI_34222095-S 1.254 2.64E213 1.377 9.30E219 212006_at 1.1622256 7.76E203
64 NM_014607 UBXD2 212008_at 1.1967869 4.48E202
65 NM_014691 AQR GI_38788371-S 1.603 3.04E240 1.573 3.89E232 212584_at 1.1355405 1.79E203
66 NM_014827 ZC3H11A GI_7662231-S 1.297 3.78E220 1.207 1.40E208 205787_x_at 1.1662422 1.14E204
67 NM_014827 ZC3H11A 205788_s_at 1.1195558 9.27E204
68 NM_015138 RTF1 GI_34222098-S 1.51 1.25E239 1.29 6.64E218 212301_at 1.0887809 2.85E202
69 NM_015235 CSTF2T GI_14149674-S 1.448 1.86E234 1.258 2.01E212 212905_at 1.1704319 5.45E203
70 NM_016167 NOL7 GI_15743546-S 1.485 8.80E228 1.55 3.28E229 202882_x_at 1.0945534 1.13E202
71 NM_016604 JMJD1B GI_38372908-S 1.406 3.16E229 1.182 3.45E209 210878_s_at 1.1330327 2.62E202
72 NM_016648 LARP7 GI_7705400-S 1.707 2.80E245 1.462 1.83E228 212785_s_at 1.1426488 6.83E203
73 NM_017426 NUP54 GI_26051236-S 1.819 1.53E248 1.404 4.29E221 218256_s_at 1.144816 2.16E203
74 NM_017730 QRICH1 GI_38570096-S 1.644 1.06E246 1.433 3.29E223 209174_s_at 1.0828506 1.54E202
75 NM_018011 ARGLU1 GI_8922258-S 1.418 1.05E225 1.349 6.49E217 218067_s_at 1.1376716 4.12E202
76 NM_021188 ZNF410 GI_10863994-S 1.507 5.98E240 1.233 4.13E212 202010_s_at 1.0814468 1.49E202
77 NM_024844 NUP85 GI_34147385-S 1.543 1.16E229 1.498 9.33E223 218014_at 1.2494535 6.29E205
78 NM_052940 LRRC42 GI_31543202-S 1.75 2.18E245 1.377 2.74E219 215084_s_at 1.0861734 3.25E202
WRN is given in bold.
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Function Function annotation P-value Molecules
1 Processing processing of mRNA 2.70E206 CDC5L, CSTF2T, HNRNPA0, NONO, PABPC1, SNW1
2 Cross-link repair cross-link repair of DNA 1.26E204 CDC5L, WRN (includes EG:7486)
3 Biosynthesis biosynthesis of ADP 1.88E204 ATP5B, ATP5C1
4 Binding binding of Gal4p binding site 3.49E204 SMARCC1, SMARCE1
5 Packaging packaging of DNA 4.48E204 MYST3, SMARCC1
6 Disruption disruption of nucleosomes 6.81E204 SMARCC1, SMARCE1
7 Transactivation transactivation of HIV-1 6.81E204 SNW1, WRN (includes EG:7486)
8 Transcription transcription 8.08E204 BTF3 (includes EG:689), BUD31 (includes EG:8896), CDC5L,
MAP3K7, MYST3, PFN1, POLR2B, PRKAR1A, PWP1, RPL6,
SMARCC1, SMARCE1, SNW1, WRN (includes EG:7486), YBX1
9 Modiﬁcation modiﬁcation of RNA 8.26E204 HNRNPC, NONO, PABPC1, RBM5
10 Expression expression of DNA 8.99E204 BTF3 (includes EG:689), BUD31 (includes EG:8896), CDC5L, MYST3,
PFN1, POLR2B, PRKAR1A, RPL6, SMARCC1, SMARCE1, SNW1,
YBX1
11 Immortalization immortalization of ﬁbroblast cell
lines
9.62E204 PRKAR1A, WRN (includes EG:7486)
12 Transactivation transactivation of HIV 1.29E203 SNW1, WRN (includes EG:7486)
13 Catabolism catabolism of ATP 1.66E203 ATP5B, ATP5C1
14 Polyadenylation polyadenylation of mRNA 1.66E203 CSTF2T, PABPC1
15 Cell division process cell division process of oocytes 2.31E203 GNAS, TPR
16 Cytostasis cytostasis of cell lines 2.66E203 METAP2 (includes EG:10988), PRKAR1A, SMARCE1, UBE3A
17 Moiety attachment moiety attachment of mRNA 2.79E203 CSTF2T, PABPC1
18 Contact growth
inhibition
contact growth inhibition of cell lines 2.94E203 METAP2 (includes EG:10988), PRKAR1A, SMARCE1
19 Cell division process cell division process of female germ
cells
3.60E203 GNAS, TPR
20 Metabolism metabolism of ATP 4.19E203 ATP5B, ATP5C1
21 Cell death cell death of tumor cell lines 4.42E203 CSNK1A1, GNAS, HNRNPA1, HNRNPC, MAP3K7, PRKAR1A, RBM5,
SMARCC1, SMARCE1, YBX1
22 Metabolic process metabolic process of ATP 4.50E203 ATP5B, ATP5C1
23 Contact growth
inhibition
contact growth inhibition of
eukaryotic cells
5.05E203 METAP2 (includes EG:10988), PRKAR1A, SMARCE1
24 Apoptosis apoptosis of tumor cell lines 5.73E203 CSNK1A1, HNRNPA1, HNRNPC, MAP3K7, PRKAR1A, RBM5,
SMARCC1, SMARCE1, YBX1
25 Processing processing of RNA 5.81E203 HNRNPC, NONO, RBM5
26 Contact growth
inhibition
contact growth inhibition 6.81E203 METAP2 (includes EG:10988), PRKAR1A, SMARCE1
27 Cell death cell death of cell lines 9.49E203 CSNK1A1, EEF1A1, GNAS, HNRNPA1, HNRNPC, MAP3K7,
PRKAR1A, RBM5, SMARCC1, SMARCE1, YBX1
28 Cell division process cell division process of germ cells 9.94E203 GNAS, TPR
29 Activation activation of HIV-1 1.14E202 SNW1, WRN (includes EG:7486)
30 Cell division process cell division process of gonadal cells 1.14E202 GNAS, TPR
31 Transactivation transactivation of Retroviridae 1.18E202 SNW1, WRN (includes EG:7486)
32 Contact growth
inhibition
contact growth inhibition of tumor
cell lines
1.23E202 PRKAR1A, SMARCE1
33 Immortalization immortalization of cells 1.28E202 PRKAR1A, WRN (includes EG:7486)
34 Splicing splicing of mRNA 1.34E202 CDC5L, SNW1
35 Transcription transcription of gene 1.94E202 BTF3 (includes EG:689), MAP3K7, MYST3, POLR2B, WRN (includes
EG:7486)
36 Transactivation transactivation of virus 2.02E202 SNW1, WRN (includes EG:7486)
37 Papillary carcinoma papillary carcinoma 2.21E202 PRKAR1A, TPR
38 Development development of animal 2.33E202 GNAS, HNRNPC, MYST3, PRKAR1A, YBX1
39 Expression expression of gene 2.35E202 BTF3 (includes EG:689), MAP3K7, MYST3, POLR2B, WRN (includes
EG:7486)
40 Developmental process developmental process of leukemia
cell lines
2.56E202 JMJD1B, MYST3, PRKAR1A
41 Splicing splicing of RNA 2.69E202 HNRNPC, NONO
42 Colony formation colony formation of ﬁbroblast cell
lines
2.90E202 PRCC, WRN (includes EG:7486)
43 Developmental process developmental process of animal 2.90E202 GNAS, HNRNPC, METAP2 (includes EG:10988), MYST3, PRKAR1A,
YBX1
44 Bipolar affective
disorder
bipolar affective disorder 2.98E202 ATP5C1, GNAS, PRKAR1A
45 Developmental
process
developmental process of organism 3.17E202 GNAS, HNRNPC, METAP2 (includes EG:10988), MYST3,
PRKAR1A, WRN (includes EG:7486), YBX1
46 Apoptosis apoptosis of eukaryotic cells 3.53E202 CSNK1A1, GNAS, HNRNPA1, HNRNPC, MAP3K7, PRKAR1A,
RBM5, SMARCC1, SMARCE1, WRN (includes EG:7486), YBX1
Continued
3870 Human Molecular Genetics, 2009, Vol. 18, No. 20sensitive to EBV in healthy individuals. Further studies are
required to evaluate this hypothesis and measurements in indi-
viduals with different COO during in vivo EBV infection might
be illuminating in this regard.
MATERIALS AND METHODS
Normalization
In the initial analysis of the Illumina Human V6 arrays used by
Stranger et al. (4) and the Affymetrix Human Focus arrays
used by Storey et al. (14), array probe set intensities that
were ,0.01 were set to 0.01. For each individual array, all
probe sets were divided by the 50th percentile of all probes
sets on that array and then each gene was divided by the
median of its measurements across all arrays. For the U133
Array Set HG-U133A and the HG-U133-Plus-2 arrays, we
applied GCRMA normalization. The expression arrays used
to determine eQTLs were normalized as described in the
Bioconductor program (27) GGtools 3.0 created by Vince
Carey (28).
Noise reduction in Stranger et al.’s data set
We intentionally pursued a highly conservative analysis to
maximize speciﬁcity. Each population was ﬁltered to include
only genes that have a 100% detection rate across all in-
vitro transcriptions (IVTs) to be compared. For the ﬁrst data
set (4): out of the 47 293 probe sets on each array [compared
between the CEU (60 samples) and YRI (60 samples) parents
and children (30 samples each) groups], only 4640 probes for
CEUp and YRIp and 4839 probes for CEUc and YRIc popu-
lations were detected at 100% across all IVTs. To determine
the IVT replication outliers, principal component analysis of
the 100% detected gene list was used. An outlier was
deﬁned as any IVT that was not within the same quarter as
Table 3. The top 20 Pearson correlation coefﬁcients (R
2), F-statistic and P-values of WRN (dependent variable) mRNA expression in a pairwise manner to all 78
probe sets cross-platform validated with ACOO differential expression
Illumina Human V6 arrays
1 and 259 degrees of freedom
Illumina probe set ID RefSeq Common Multiple R
2 Adjusted R
2 F-statistic P-value ( 10
216)
1 GI_19924171-S NM_000553 WRN 1.000 1.000 5.15E þ 33 ,2.2
2 GI_19718761-A NM_000462 UBE3A 0.837 0.836 1329 ,2.2
3 GI_38570096-S NM_017730 QRICH1 0.809 0.808 1097 ,2.2
4 GI_7705400-S NM_016648 LARP7 0.790 0.790 976 ,2.2
5 GI_34147516-S NM_001025105 CSNK1A1 0.782 0.781 927.1 ,2.2
6 GI_21735565-A NM_003188 MAP3K7 0.780 0.779 915.8 ,2.2
7 GI_26051236-S NM_017426 NUP54 0.767 0.766 853.7 ,2.2
8 GI_27597083-S NM_006838 METAP2 0.763 0.763 835.6 ,2.2
9 GI_34222098-S NM_015138 RTF1 0.763 0.762 833.3 ,2.2
10 GI_31543202-S NM_052940 LRRC42 0.761 0.760 826.3 ,2.2
11 GI_5902033-S NM_007062 PWP1 0.731 0.730 704.2 ,2.2
12 GI_38788371-S NM_014691 AQR 0.724 0.723 678.4 ,2.2
13 GI_21626463-S NM_001655 ARCN1 0.721 0.720 669 ,2.2
14 GI_16357499-S NM_001253 CDC5L 0.719 0.718 661.8 ,2.2
15 GI_10863994-S NM_021188 ZNF410 0.715 0.714 648.4 ,2.2
16 GI_4505940-S NM_000938 POLR2B 0.708 0.707 62808 ,2.2
17 GI_31317304-S NM_005791 MPHOSPH10 0.705 0.704 618.4 ,2.2
18 GI_13491165-S NM_001020658 PUM1 0.696 0.695 593.5 ,2.2
19 GI_17986281-S NM_003463 PTP4A1 0.695 0.694 590.9 ,2.2
20 GI_19923363-S NM_006628 ARPP-19 0.690 0.689 577.2 ,2.2
21 GI_8922258-S NM_018011 ARGLU1 0.690 0.689 57607 ,2.2
The eight boldfaced genes are part of the ﬁnal immortalization network.
Table 2. Continued
Function Function annotation P-value Molecules
47 Primary tumor primary tumor 3.97E202 EEF1A1, GNAS, HNRNPA1, LARP7 (includes EG:51574), METAP2
(includes EG:10988), PFN1, PRCC, PRKAR1A, TPR, UBE3A,
WRN (includes EG:7486)
48 Synthesis synthesis of protein 4.21E202 EEF1A1, METAP2 (includes EG:10988), NACA, RPL6
49 Tumorigenesis tumorigenesis of tumor cell lines 4.75E202 GNAS, PRKAR1A
50 Cell death cell death of eukaryotic cells 4.77E202 CSNK1A1, EEF1A1, GNAS, HNRNPA1, HNRNPC, MAP3K7,
PRKAR1A, RBM5, SMARCC1, SMARCE1, WRN (includes
EG:7486), YBX1
51 Gastric carcinoma gastric carcinoma 4.84E202 LARP7 (includes EG:51574), PRCC
Bold values indicate biological functions with WRN enrichment.
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PC2 (y-axis) (Supplementary Material, Fig. S1). There had to
be at least three IVTs grouped for each cell line for inclusion
in the analysis. The gene intensity variation across replicated
IVTs within a population was ﬁltered to include only those
probes sets with a +0.5 standard deviation of the mean.
This resulted in the following sets of population-consistent
probe sets: YRIp 3121 probe sets, CEUp 2759 probe sets,
YRIc 1640 probe sets and CEUc with 1520 probe sets whose
combined expression ranges were within a one standard devi-
ation band spanning the population mean. Differentially
expressed probe sets were identiﬁed using one-way ANOVA
(false discovery rate of 0.01, t-test with unequal variance
and Bonferroni correction for multiple testing). We then
obtained the intersection of the population-consistent probe
sets across YRIp and CEUp identifying 1043 such
probe sets. We compared the mean expression of the 1043
probe sets between CEUp and YRIp (t-test with P-value ¼
0.01 and Bonferroni correction), resulting in 958 probe sets
that were signiﬁcantly different between CEUp and YRIp
populations. Within the CEUc versus YRIc populations, there
were 607 shared probe sets that were population consistent
in their respective populations. We compared the mean
expression differences of 607 probe sets between CEUc and
YRIc using t-test as previously described; this resulted in
568 probe sets that were signiﬁcantly different between
CEUc and YRIc populations. Of the above 958 and 568 differ-
entially expressed probes, 228 probe sets were differentially
expressed in both parent and child populations. When the
same analysis was performed applying the same rigorous ﬁl-
tering on a smaller data set of eight CEU and eight YRI
founder males, the only gene differentially expressed was
WRN on the Affymetrix Human Focus Array (14).
The 228 probe sets’ network analysis
We used the Ingenuity Pathways Analysis program (IPA—
Ingenuity
w Systems, www.ingenuity.com) to analyze the set
of differentially expressed probe sets. Of the 228 probe sets,
we exclude 11 expressed sequence tags (ESTs), and the
remaining 217 probe sets were mapped into IPA with 140 of
the 217 probe sets speciﬁcally mapping into the functions/
pathways by RefSeq accession numbers. With removal of
redundant gene symbols, 101 genes in total enriched 269 func-
tions and diseases annotations (FAs). Of the 269 FAs signiﬁ-
cantly enriched within the 228 probe list, we removed 237
enriched FAs that had less than three genes, P-values .0.05
and/or redundant names, resulting in a ﬁnal 32 FA categories
enriched in the differentially expressed gene list comparing
CEU and YRI samples. The 32 enriched FAs are comprised
Table 4. The 24 immortalization probe set Ids and ACOO expression differences in P-values for SekWon et al.’s primary LBC data set
(Affymetrix.GeneChip.HG-U133_Plus_2), Yelensky et al.’s (Affymetrix.GeneChip.HG-U133A) and Stranger et al.’s (Illumina WGA-6) immortalized LBC
data sets
Gene symbol EBV immortalized B cells Non-immortalized B cells
Illumina V-6 (CEU/YRI) AHG-U133A (CEU/YRI) HG-U133_Plus_2 (CA/AA)
Gene/probe ID Fold change P-value (,0.05) Gene/probe ID Fold change P-value (,0.05) Fold change P-value (,0.05)
ARCN1 GI_21626463-S 1.5 5.84E255 201176_s_at 1.1 1.67E203 No signiﬁcant difference
ATP5B GI_32189393-S 1.4 1.38E248 201322_at 1.1 2.77E203 No signiﬁcant difference
BAT1 GI_45580710-I 1.2 3.13E221 200041_s_at 1.2 1.27E205 1.5 1.67E203
212384_at 1.2 2.10E202 1.9 1.66E203
CDC5L GI_16357499-S 1.5 2.48E261 209055_s_at 1.2 1.92E203 2.3 1.83E205
209056_s_at 1.1 2.60E202 1.8 1.74E203
DNAJA1 GI_4504510-S 1.8 4.77E255 200880_at 1.1 1.67E202 2.4 2.68E204
200881_s_at 1.2 2.91E204 4.4 3.11E210
EXO1 GI_39995067-I 1.04 4.04E205 204603_at 1.2 2.57E205 No signiﬁcant difference
GI_39995068-A 1.8 1.04E259
FEN1 GI_19718776-S 1.8 1.64E255 204768_s_at 1.4 2.20E204 1.3 5.06E203
JMJD1B GI_38372908-S 1.3 3.65E237 210878_s_at 1.69E202 No signiﬁcant difference
NOL7 GI_15743546-S 1.5 8.37E255 202882_x_at 1.1 6.93E203 1.3 2.06E202
NUP54 GI_26051236-S 1.6 6.19E265 218256_s_at 1.1 1.22E203 No signiﬁcant difference
NUP62 GI_34335245-A 1.4 4.41E233 207740_s_at 1.2 2.74E202 1.3 2.65E202
PFN1 GI_16753213-S 1.2 5.76E225 200634_at 1.1 3.06E202 No signiﬁcant difference
PLRG1 GI_4505894-S 1.5 3.68E253 225194_at No Probe 1.4 2.06E202
POLR1A
a GI_7661685-S 1.3 1.66E209 222704_at No Probe 1.2 1.34E203
POLR2B GI_4505940-S 1.5 3.80E258 201803_at 1.1 2.25E202 No signiﬁcant difference
PRCC GI_40807446-S 1.5 1.14E254 208938_at 1.1 7.89E203 No signiﬁcant difference
PSME3 GI_30410793-A 1.8 2.07E245 200987_x_at 1.2 3.51E203 1.6 2.94E205
209853_s_at 1.2 2.51E203 1.6 1.13E205
PUM1 GI_13491165-S 1.3 1.10E237 201164_s_at 1.1 3.39E204 No signiﬁcant difference
PWP1 GI_5902033-S 1.5 5.68E258 201608_s_at 1.1 2.51E203 No signiﬁcant difference
SFRS2 GI_4506898-S 1.9 1.45E262 200753_x_at 1.2 1.22E203 1.4 2.06E202
VCP GI_7669552-S 1.3 1.78E217 208649_s_at 1.2 3.47E204 1.3 2.12E202
WRN GI_19924171-S 1.8 1.36E273 205667_at 1.2 3.53E203 No signiﬁcant difference
ZNF410 GI_10863994-S 1.4 1.67E251 202010_s_at 1.1 9.10E203 No signiﬁcant difference
ZNF512B GI_34013527-S No signiﬁcant difference 55872_at No signiﬁcant difference 1.2 3.86E202
Bold values indicate WRN gene signiﬁcant difference across all three platforms.
aGene with population speciﬁc eQTL.
3872 Human Molecular Genetics, 2009, Vol. 18, No. 20of 87 (86%) of the overall 101 genes annotated in FAs by the
IPA package (Data not shown).
Viral titers
Cell-line-speciﬁc viral titers were shared with us courtesy of
David Altshuler and Roman Yelensky (Broad Institute,
Cambridge, MA, USA). Relative EBV copy number was deter-
mined by the difference of CT method (2) and log-transformed.
EBV measurements were obtained when cell-lines were ﬁrst
received from the Coriell Institute in 2005.
Cross platform validation of the 228 genes in Yelensky
et al. affymetrix data set
The 228 genes identiﬁed with COO differential expression from
Strangeretal.samples(Illuminaplatform)werevalidatedacross
platforms using an independent study of the same samples from
the CEU and YRI populations on the Affymetrix GeneChip
Human Genome U133 Array Set HG-U133A (15). The initial
228-gene list mapped to 352 probe sets on the HG-U133A
array by RefSeq accession number. Of the 228 genes that were
signiﬁcantly different on the Illumina platform between CEU
andYRI,therewere78probesetsofthesamegenesthatweresig-
niﬁcantly different at a P-value cutoff of 0.05 with Benjamini–
HochbergmultipletestingcorrectionontheAffymetrixplatform.
TheWRNgenewasalsoamongthegenesthatweresigniﬁcantly
different on the Affymetrix platform, a ﬁnding that was con-
ﬁrmed in a third independent study of Storey et al.’s data on
the Affymetrix Human Focus Arrays.
Squared Pearson correlation coefﬁcients (R
2)
We preformed a liner regression analyses to determine the
squared Pearson correlation coefﬁcients (R
2) and P-values of
WRN (dependent variable) mRNA expression in a pairwise
manner to all 78 probe sets cross-platform validated with
ACOO differential expression. We reported the genes with
an R
2 cutoff of 0.7 or greater (Table 3).
Intersection of the immortalized cell gene list with the
non-immortalized signiﬁcantly different gene list
We used an in house unpublished data set of AA and CA
samples consisting of 43 male and female children from 1 to
16 years of age. These samples were collected as control
samples in an unrelated study of autism spectrum disorder
(ASD). LCs were isolated and RNA extracted (without
EBV immortalization) and hybridized to the Affymetrix
U133plus2 array. The initial 228 gene list mapped to 352
probe sets on the U133plus2 array by RefSeq accession
number. Statistical inference was determined using parametric
test; variance assumed unequal Student’s t-test, P-value cutoff
0.05, with Benjamini-Hochberg multiple test correction.
Of the 524 across platform-intersected probes, 288 probe
sets had signiﬁcant difference between the AA and CA
cohorts. We cross array (U133Pluse2 to U133A) matched
the RefSeq numbers of the 288 probes yielding 299
probes for intersection across platforms. We intersected
the 299 probe sets with the across platform conﬁrmed 78
Figure 3. Of the 78 probe sets cross-platform validated with ACOO differential expression, 16 (80%) of the top 20 WRN-correlated genes (R
2 between 0.69 and
0.84) grouped with WRN into one biological functions network associated with gene expression, infection mechanism and cancer with an enrichment P-value of
1.0   10
247.
Human Molecular Genetics, 2009, Vol. 18, No. 20 3873probe sets that have discordant expression between CEU and
YRI trios.
Immortalization network enrichment
Twelve of the 14 probe sets identiﬁed as immortalized cell
speciﬁc were enriched in IPA and mapped to 12 independent
genes (two were unmapped ESTs). The genes clustered into
3 networks with 10 genes mapped into the top network of
DNA replication, recombination and repair with a P-value of
10
227. JMJD18 and PUM1 mapped separately to Networks
2 and 3. The 10 genes from Network 1 were exported into
IPA editor to construct the ‘Immortalization Network’ includ-
ing JMJD18 and PUM1. To determine whether any of
these additional genes have signiﬁcant ACOO differential
expression (subsequent to ﬁnding the marked network enrich-
ment score), we relaxed the statistical inference cutoffs in
three ways. First, we no longer ﬁltered the genes to meet the
intra-population consistency criterion. Second, we relaxed
the P-value cutoff from 0.01 to 0.05 and, ﬁnally, we
changed the multiple test correction to Benjamini–Hochberg
from Bonferroni for statistical inference for the Illumina Plat-
form only.
ACOO-speciﬁc eQTLs
The eQTLs were determined using the Bioconductor program
(27) GGtools 3.0 written by Vince Carey. Here we used only
Figure 4. Twelve of the 14 probe sets identiﬁed in the Venn diagram with immortalized cell-speciﬁc differential expression (circled in Venn diagram), mapped to
12 independent genes in Ingenuity Pathway program to construct the ‘immortalization network’. The 12 independent genes are depicted in red. POLR1A which
has an heritable eQTL in the YRI population with signiﬁcant differential expression by ACOO is in green. The additional genes with ACOO signiﬁcantly differ-
ent expression but are not immortalization speciﬁc are in yellow.
3874 Human Molecular Genetics, 2009, Vol. 18, No. 20the founder population (60 parents) for the CEU and YRI
cohorts. A relevant eQTL was only determined to be of inter-
est when it was discordant for signiﬁcance across the YRI and
CEU populations. A signiﬁcant cis eQTL is deﬁned as having
an SNP correlated to a gene’s expression within 50 kb from
the 50 or 30 end of the gene with a signiﬁcant P-values less
than or equal to –log10 10
28.
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Supplementary Material is available at HMG online.
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